Is Airsupra (albuterol/budesonide) more effective than a standard albuterol inhaler for adults (≥ 18 years) with asthma that is not well‑controlled on maintenance inhaled corticosteroid or who have frequent exacerbations?

Is Airsupra Better Than Albuterol Inhaler?

Yes, Airsupra (albuterol/budesonide combination) is superior to albuterol alone for adults ≥18 years with moderate-to-severe asthma who remain uncontrolled despite maintenance inhaled corticosteroid therapy, as it significantly reduces severe exacerbations by 26-28% while providing equivalent bronchodilation. 1, 2

FDA-Approved Indication and Evidence Base

Airsupra is FDA-approved specifically for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma ≥18 years of age 1. This represents a paradigm shift from traditional SABA-only rescue therapy.

The pivotal MANDALA trial (n=3,132 patients, 97% adults) demonstrated that Airsupra 180/160 mcg reduced the risk of severe asthma exacerbations by:

• 26% reduction in time to first severe exacerbation (HR 0.74; 95% CI: 0.62-0.89; p=0.001) 2
• 28% reduction in overall exacerbation risk (HR 0.72; 95% CI: 0.60-0.86; p<0.001) 1
• 24% reduction in annualized exacerbation rate (0.46 vs 0.60 events/year; p=0.008) 1

Clinical Superiority Beyond Bronchodilation

Exacerbation Prevention

The key advantage is addressing both bronchoconstriction and inflammation simultaneously during symptom worsening. Traditional albuterol-only rescue therapy fails to address the inflammatory component that drives exacerbations 3. Airsupra intervenes during this "window of opportunity" when patients experience breakthrough symptoms, delivering anti-inflammatory therapy precisely when needed 3.

Systemic Corticosteroid Burden

Airsupra reduced the annualized total systemic corticosteroid dose by 40 mg per patient (87 mg vs 127 mg with albuterol alone) 1. This is clinically meaningful for reducing long-term steroid-related adverse effects.

Asthma Control and Quality of Life

• 67% vs 63% achieved clinically meaningful improvement in asthma control (ACQ-5 responders; odds ratio 1.21; 95% CI: 1.01-1.46) 1
• 52% vs 47% achieved improved quality of life (AQLQ responders; odds ratio 1.22; 95% CI: 1.01-1.47) 1

Bronchodilation Equivalence

The DENALI trial confirmed that both components contribute to efficacy 4:

• Onset of bronchodilation: median 7.5 minutes (Airsupra) vs 10.0 minutes (albuterol)
• Duration: mean 186.9 minutes vs 167.9 minutes
• Day 1 bronchodilation was comparable between groups 1, 4

This is critical: Airsupra provides the same rapid symptom relief as albuterol while adding exacerbation protection 4.

Safety Profile

Airsupra's safety profile is comparable to albuterol alone, even with regular use 1, 5:

• Adverse event frequencies were similar between groups
• ICS-associated adverse events (oral candidiasis, dysphonia) occurred in ≥1% but were manageable 1
• Mean daily use was similar: 2.6 inhalations/day (Airsupra) vs 2.8 (albuterol) 5
• High daily use (≥8 inhalations/day) was rare in both groups 5

Critical safety consideration: Maximum dose is 6 doses (12 inhalations) per 24 hours 1. Patients should rinse mouth after use to prevent oral candidiasis 1.

Guideline Context and Patient Selection

The 2020 NAEPP guidelines support the concept of as-needed ICS plus SABA for mild persistent asthma in patients ≥12 years, noting this approach is equivalent to daily ICS for asthma control, quality of life, and exacerbations 6. However, these guidelines predate Airsupra's approval and the MANDALA trial data.

Who Benefits Most from Airsupra:

1. Adults ≥18 years with moderate-to-severe asthma on maintenance ICS-containing therapy who still experience breakthrough symptoms 1, 2
2. Patients with history of exacerbations (benefit seen regardless of 1 or >1 exacerbation in past year) 1
3. Patients across the spectrum of baseline lung function and asthma severity 1

Who Should Use Standard Albuterol:

1. Patients <18 years (Airsupra not approved in this population) 1
2. Well-controlled mild asthma requiring only occasional rescue therapy
3. Patients with hypersensitivity to budesonide 1

Important Caveats

• Airsupra is NOT a maintenance therapy and should not be used for single maintenance and reliever therapy (SMART) 3
• If symptoms continue after using Airsupra, this signals asthma destabilization requiring treatment reevaluation 1
• Patients must continue their prescribed maintenance therapy; Airsupra is used in addition to, not instead of, controller medications 2
• Use with caution with strong CYP3A4 inhibitors (e.g., ritonavir) due to potential systemic corticosteroid effects 1

Bottom Line Algorithm

For adults ≥18 years with asthma:

• Moderate-to-severe asthma on maintenance ICS therapy with breakthrough symptoms → Use Airsupra as rescue therapy
• Mild persistent asthma, age ≥12 years → Either daily low-dose ICS + albuterol rescue OR as-needed ICS + SABA concomitantly (per 2020 guidelines) 6
• Well-controlled mild asthma or age <18 years → Standard albuterol remains appropriate

The evidence unequivocally demonstrates that Airsupra is superior to albuterol alone for reducing exacerbations in the approved population, representing a meaningful advance in asthma rescue therapy 2, 3.